The overall pipelineThinking on the competition for BCG therapy I remain convinced that the key to longterm success is as follows.
- get BTD to show wider pool of investors that serious drug with good outcomes and FDA respect despite being a tiny tiny company on the tsx venture
- get a financial bump of some kind with the BTD
- use the money to widen the pipeline to show IV rutherrin could do amazing things for typically fatal GBM and advanced NSCLC
- get some kind of thing going with very interesting HSV data to further show the different pipelines
If they can show the world that not a one trick NMIBC pony then they will shoot up as the more viable avenues of sucess = more derisking compared to one drug and one narrow disease type of biotech company.